FDA wants to fast-track treatments for C. diff

Share this article:

Clostridium difficile poses a serious public health threat and potential treatments should be fast-tracked, the Food and Drug Administration stated in a newly proposed regulation.
 
The proposed rule would enact the Generating Antibiotic Incentives Now (GAIN) provision of the Food and Drug Administration Safety and Innovation Act of 2012. The provision provides for fast-tracked review of antibiotic and antifungal drugs that would treat especially dangerous pathogens. GAIN would also extend the market exclusivity of these drugs by five years.
 
The FDA has identified 18 qualifying pathogens for GAIN inclusion, including C. diff. The “high prevalence of C. difficile infections,” the emergence of fatal, antibiotic-resistant strains, and “very limited treatment options” justify the inclusion of C. diff. as a qualifying pathogen, the FDA stated in Tuesday's Federal Register
 
The move to prioritize C. diff treatments comes on the heels of an FDA decision to tighten regulations around fecal transplants. These have proven effective in treating C. diff by repopulating the gut with needed bacteria that are destroyed by antibiotics. Some eldercare professionals have criticized the FDA, saying more stringent transplant oversight is burdensome and unnecessary, and further limits treatment options. 
 
Other pathogens on the GAIN list include streptococcus pneumoniae and EnterobacteriaceaeS. pneumoniae leads to outbreaks of pneumococcal disease in nursing homes. Carbapenem-resistant Enterobacteriaceae is an especially deadly, drug-resistant “super bug” that has increasingly struck long-term care facilities.
 
Click here to access the complete Federal Register entry. Comments will be accepted through Aug. 12.
 
Share this article:

More in News

Nursing home antipsychotic use has dipped nearly 19% under national effort, latest figures show

Nursing home antipsychotic use has dipped nearly 19% ...

The percent of long-stay nursing home residents receiving antipsychotic medication has decreased 18.8% under a nationwide initiative that started in 2012.

Jimmo succeeds in getting Medicare coverage, two years after landmark case ended

Glenda Jimmo has reached a settlement with the federal government and will finally receive Medicare coverage for claims that were denied in 2007, which led her to file a class-action lawsuit over the so-called "improvement standard."

Breier named new CEO at Kindred

Breier named new CEO at Kindred

Kindred Healthcare announced Thursday that it has chosen a new top executive to lead its push toward creating a mammoth national brand. Benjamin A. Breier, the company's current president and ...